Characteristic | Number = 121 | % | |
---|---|---|---|
Menopausal status | Premenopausal | 60 | 49.6 |
Postmenopausal | 61 | 50.4 | |
Clinical staging | IIA | 19 | 15.7 |
IIB | 34 | 28.1 | |
IIIA | 40 | 33.1 | |
IIIB | 8 | 6.6 | |
IIIC | 20 | 16.5 | |
Clinical staging primary tumor | cT1-2 | 52 | 43.0 |
cT3-4 | 69 | 57.0 | |
Clinical staging nodes | cN0 | 39 | 32.2 |
cN1 | 36 | 29.8 | |
cN2-3 | 46 | 38.0 | |
Tumor type | Ductal invasive | 113 | 93.4 |
Lobular invasive | 5 | 4.1 | |
Other | 3 | 2.5 | |
Tumor grade | GI | 7 | 5.8 |
GII | 39 | 32.2 | |
GIII | 61 | 50.4 | |
Unknown | 14 | 11.5 | |
Hormone-sensitivity | Negative | 39 | 32.2 |
Positive | 80 | 66.1 | |
No data | 2 | 1.7 | |
HER2 overexpression | Negative | 87 | 71.9 |
Positive | 29 | 24.0 | |
Unknown | 5 | 4.1 | |
Triple negative | No | 90 | 74.4 |
Yes | 26 | 21.5 | |
Unknown | 5 | 4.1 | |
IHC subtype | ER+ and/or PR+ and HER2- | 61 | 50.4 |
ER+ and/or PR+ and HER2+ | 16 | 13.2 | |
ER- and PR- and HER2+ | 13 | 10.7 | |
ER- and PR- and HER2- | 26 | 21.5 | |
Non classifiable | 5 | 4.1 | |
Chemotherapy regimen | AC x 4 – Docetaxel x 4 | 97 | 80.2 |
Sequential anthracyclines-paclitaxel | 10 | 8.3 | |
Non anthracycline | 2 | 1.7 | |
Non anthracycline-taxane | 4 | 3.3 | |
Concomitant anthracyclines–taxane | 8 | 6.6 | |
Trastuzumab treatment | No | 99 | 81.8 |
Neoadjuvant | 17 | 14.0 | |
Adjuvant | 5 | 4.1 | |
Local treatment | Mastectomy | 67 | 55.3 |
Breast conservation surgery (BCT) | 53 | 43.8 |